RxDoctor Payments Data

Wills Geils, MD

Cardiology · Charleston, SCNPI 1902901903

Payments from drug & device makers

$5,232in general payments, 2019–2025

Across 190 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vital Connect, Inc$682
  • Boston Scientific$498
  • Philips North America LLC$458
  • Abbott$401
  • Pfizer$383
  • E.r. Squibb & Sons, L.L.C.$285
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$5,232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$423,199
Medicare patients
1,404
Services billed
5,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban692$765,577
VyndamaxTafamidis15$378,530
VyndaqelTafamidis Meglumine13$285,842
EntrestoSacubitril/Valsartan110$122,178
XareltoRivaroxaban75$104,524
JardianceEmpagliflozin96$75,669
Repatha SureclickEvolocumab42$43,837
Repatha SyringeEvolocumab12$17,407
Metoprolol Succinate870$14,199
Diltiazem 24hr Er (Cd)Diltiazem Hcl327$10,089
BrilintaTicagrelor12$6,544
Rosuvastatin Calcium369$6,512
LivaloPitavastatin Calcium11$6,268
Praluent PenAlirocumab12$5,664
Ezetimibe154$5,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax, Vyndaqel$383$1,429,949720 claims
NovartisEntresto$187$122,178110 claims
Johnson & JohnsonXarelto$31$104,52475 claims
Boehringer IngelheimJardiance$112$75,66996 claims
AstraZenecaBrilinta$131$6,54412 claims
Kowa Pharmaceuticals America, Inc.Livalo$30$6,26811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other cardiology in Charleston

Where these figures come from

Is this you, or does something look wrong? →